At Biogen, our mission is clear: we are pioneers in neuroscience. Since our founding in 1978 as one of the world’s first global biotechnology companies, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases.
We believe that no other disease area holds as much need or as much promise for medical breakthroughs as neuroscience. Our focus on neuroscience, our deep scientific expertise and our courage to take risks make us leaders in the research and development of medicines to transform neuroscience to benefit society.
We work to have an impact beyond our medicines as we strive to improve patient health outcomes, solve social and environmental challenges, cultivate a workplace that enables our employees to thrive, support local communities, and inspire future generations of scientists. This is central to our mission and vital to our growth. To us, this is science that matters.
Engaged 50 suppliers in climate change strategy, representing 75% of greenhouse gas (GHG) emissions from supply chain
Carbon neutral company since 2014
Biogen products treat 38% of MS patients worldwide
48% of director-level positions are held by women
3,000 employees in 25 countries supported 62 projects as part of Care Deeply Day in 2016
$6.2 million in community grants and Biogen Foundation matching donations
4,960 students participated in our Community Lab to learn more about science
Nearly $202 million spend with small and diverse businesses
About the report
Our 2016 Global Impact Report contains data from calendar year 2016. In some instances, we include information on initiatives or activities that may have begun in 2016 but have continued into 2017.
This report was prepared in accordance with the Global Reporting Initiative (GRI) G4 Guidelines at the “core” option. Please refer to the GRI Index to see which material aspects and relevant indicators are reported, as well as how we track our efforts in alignment with the U.N. Sustainable Development Goals (SDGs).
Learn more about how we report against the relevant GRI indicators and SDGs in the About This Report section of our 2016 Global Impact Report.
Since 2009, Biogen has conducted report materiality assessments informed by the Global Reporting Initiative (GRI) Principles for Defining Report Content to identify and prioritize the corporate responsibility topics and issues most important to the company and its stakeholders. The process in 2016 involved external stakeholder interviews; desk research to establish the broader sustainability context; an internal visioning workshop to prioritize and validate the issues; and external stakeholder meetings to review the findings and gather their feedback.
The 18 issues that were identified in the 2016 GRI materiality assessment are presented in the matrix below. Access to treatments, investments in R&D to ensure a robust pipeline, and improving patient outcomes are Biogen’s highest priorities. But we consider everything in this matrix to be material and important from a corporate responsibility perspective. Throughout our 2016 Global Impact Report, we explain how Biogen is addressing these issues and measuring performance.
We recognize the powerful role that business can play in making the United Nations’ Sustainable Development Goals (SDGs) a reality. The SDGs comprise 17 goals and 169 associated targets that incorporate the economic, social and environmental dimensions of sustainable development. At Biogen, we support all 17 goals and encourage all businesses to consider how they may also contribute. We have been refining our own Global Impact Strategy to align with the SDGs that are most relevant to our business and to further support Science That Matters.
You are now leaving Biogen’s corporate website.
Third Party Sites
Biogen assumes no responsibility nor does it control, endorse or guarantee any aspect of your use of any third party sites. Additionally, the presence of this link does not imply the third party site's endorsement of Biogen or this website.